INVIGORATE-2 RCT of IV secukinumab in PsA. Demonstrates efficacy as expected. My big question is why are we doing trials like this against placebo? Surely a non-inferiority vs s/c secukinumab is more ethical. Abstr#0776 #ACR23 @RheumNow https://t.co/Usw0iwZEF5 https://t.co/DP6Gb4pF8a

Do you think point of care #ultrasound should be mandatory in #rheumatologu #residency #training? @RheumNow @ACRheum #ACR23

A good clinical trial should consist of not denying a standard of care comparator. Difficult to enrol in protocols requiring placebo in active disease. Maybe learn from #ped #rheum #RCTs where all get active #Rx then randomized to stop vs continue&trial designs. @RheumNow #ACR23 https://t.co/eQFEktsfBt

A woman who knows how to integrate fashion into science. @ashira_md noted how TLR’s look like the Chanel brand @CHANEL #ACr23 @RheumNow @uptoTate @AWIRGROUP @gwenesta_melton #ScienceIsCool https://t.co/GQro9xR71W

SLE Prosp Observational Cohort Study (SPOCS) reported realworld data on meds use in mod-to-severe SLE: ⬆️in GC dose in 1st 6mos then stable thru 36mos w/ stable antimalarials, mod⬆️in biologics, IS Key message? Addt'l tx needed to avoid high GC doses #ACR23 ABST0592 @RheumNow https://t.co/q5YGYKNG6S

RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow and its faculty.

CV events in women w/ ARDs pregnancies: -2.0% of 19,340 pregnant ARDs Adjusted relative risk: -4 fold in ARD -15 fold in primary APS -6 fold in SLE -SLE + APS 18 fold 25-30% occur in early post partum! Need for continued vigilance after delivery @RheumNow #ACR23 ABST0722 https://t.co/hLeN61WBnB

CVE’s higher in pregnant pts with SLE + APS, primary APS and Lupus nephritis especially in the postpartum period. Rheums need to be involved with their patients’ care during pregnancy! Abstr#0722 #ACr23 @rheumnow https://t.co/P6sbJtd6xW

Always great to see UCSD represent at #ACR23! Pregnant women with rheumatic diseases and antiphospholipid syndrome higher a HIGHER risk for acute cardiovascular events 30% of events occurred postpartum @RheumNow Abs#0722 https://t.co/CqZedfOlBC

#ACR23 Real-world multicentre study showed steroid-sparing effect of Belimumab in #SLE. At 2 years, proportion of patients on =>10mg/d decreased from 52% to 3%. 18% and 13% achieved LLDAS and DORIS remission. Support its use esp. in those relying on glucocorticoids @RheumNow https://t.co/ad5XH3pmYc

Systemic anti-inflammatory treatments for PsO and PsA including methotrexate and biologics provided cardioprotective effects Potential cardiovascular benefits of IL-17i and IL-12/23i compared to TNFi @RheumNow #ACR23 Abs#0498 https://t.co/Np7PSNvFd6

#ACRBest @RheumNow https://t.co/u6DiQbebTF

Plenary 1 #ACR23 CVE in ARD/APS is a significant risk factor during pregnancies and the risk stays even after delivery for a significant amount of time. California based administrative data study! abst#722 @RheumNow https://t.co/HawhS4Gqko

Treatment intensification was associated with a higher ASDAS cut-off (2.7) value than the recommended one (≥2.1), the recommended cut-off could be too stringent or consider other factors than disease activity, Webers, El-Din Abst#0517 #ACR23 @RheumNow https://t.co/ZtBXhufxU1 https://t.co/MzvZQoFbvw

Should all of active moms with #SLE receive DVT prophylaxis post partum? High rates of VTE in #ARDs post partum #0722 #ACRbest #ACR23 @RheumNow @ACRheum Likely data driven by #SLE and maybe #RA and not all #autoimmune #rheumatic #disease. Large pop’n data from California https://t.co/sGJa5N6HUj